{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T09:12:18Z","timestamp":1768209138954,"version":"3.49.0"},"reference-count":19,"publisher":"BMJ","issue":"11","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2025,10,23]]},"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:p>Renal cell carcinoma (RCC) comprises a heterogeneous group of neoplasms with variable prognoses. Chromophobe RCC, a relatively uncommon subtype, generally follows an indolent clinical course but may occasionally exhibit aggressive or metastatic behaviour. This report describes a woman in the mid 60s with a history of partial nephrectomy for chromophobe RCC who subsequently developed metastatic disease. Systemic treatment with cabozantinib was initiated, resulting in dermatological toxicity. Serial imaging over 4 years demonstrated progressive metastatic involvement, including hepatic lesions. This account underscores the challenges of managing metastatic chromophobe RCC, differentiating true recurrence from potential second primary malignancies and addressing the adverse effects of targeted therapies such as cabozantinib.<\/jats:p>","DOI":"10.1136\/bcr-2025-266596","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T04:10:15Z","timestamp":1762402215000},"page":"e266596","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Chromophobe renal cell carcinoma with metastatic progression and cabozantinib-induced hand\u2013foot syndrome"],"prefix":"10.1136","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4475-3501","authenticated-orcid":false,"given":"Omer","family":"Esmez","sequence":"first","affiliation":[{"name":"Orthopedics and Traumatology, Elaz\u0131g Fethi Sekin City Hospital, El\u00e2zig, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merve","family":"Y\u0131ld\u0131z Esmez","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Departmant of Internal Medicine, Firat University, El\u00e2zig, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guln\u0130hal","family":"Deniz","sequence":"additional","affiliation":[{"name":"Erzurum Technical University, Erzurum, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"key":"2025120102403359000_18.11.e266596.1","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12020413","article-title":"Adverse Events of Cabozantinib as a Potential Prognostic Factor in Metastatic Renal Cell Carcinoma Patients: Real-World Experience in a Single-Center Retrospective Study","volume":"12","author":"Doma\u0144ski","year":"2024","journal-title":"Biomedicines"},{"key":"2025120102403359000_18.11.e266596.2","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1080\/14740338.2024.2429475","article-title":"Safety assessment of cabozantinib in patients with renal cell carcinoma: retrospective pharmacovigilance study based on FAERS database","volume":"24","author":"Wang","year":"2025","journal-title":"Expert Opin Drug Saf"},{"key":"2025120102403359000_18.11.e266596.3","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/ced.12694","article-title":"Incidence and risk of hand-foot skin reaction with cabozantinib, a novel multikinase inhibitor: a meta-analysis","volume":"41","author":"Belum","year":"2016","journal-title":"Clin Exp Dermatol"},{"key":"2025120102403359000_18.11.e266596.4","doi-asserted-by":"crossref","DOI":"10.3390\/medicina60030398","article-title":"Analysis of Factors Contributing to Adverse Events and Evaluation of Their Impact on Prognosis in Metastatic Renal Cell Carcinoma Patients-Real-World Experience in a Single-Center Retrospective Study and Narrative Review","volume":"60","author":"Doma\u0144ski","year":"2024","journal-title":"Medicina (Kaunas)"},{"key":"2025120102403359000_18.11.e266596.5","doi-asserted-by":"crossref","unstructured":"Kucharz J , Budnik M , Dumnicka P , et al . Hand-foot syndrome and progression-free survival in patients treated with sunitinib for metastatic clear cell renal cell carcinoma. In: Advances in Medicine and Medical Research. 2019: 35\u201340.","DOI":"10.1007\/5584_2018_328"},{"key":"2025120102403359000_18.11.e266596.6","doi-asserted-by":"crossref","first-page":"619","DOI":"10.2147\/TCRM.S251673","article-title":"An Evaluation of Cabozantinib for the Treatment of Renal Cell Carcinoma: Focus on Patient Selection and Perspectives","volume":"18","author":"Iaxx","year":"2022","journal-title":"Ther Clin Risk Manag"},{"key":"2025120102403359000_18.11.e266596.7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2042.2012.03079.x"},{"key":"2025120102403359000_18.11.e266596.8","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1001\/jamadermatol.2014.2734","article-title":"Cutaneous adverse effects associated with the tyrosine-kinase inhibitor cabozantinib","volume":"151","author":"Zuo","year":"2015","journal-title":"JAMA Dermatol"},{"key":"2025120102403359000_18.11.e266596.9","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1026978","article-title":"The value of the multidisciplinary team in metastatic renal cell carcinoma: Paving the way for precision medicine in toxicities management","volume":"12","author":"Roberto","year":"2022","journal-title":"Front Oncol"},{"key":"2025120102403359000_18.11.e266596.10","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2012.434"},{"key":"2025120102403359000_18.11.e266596.11","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/bjc.2015.419","article-title":"Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer","volume":"114","author":"Zielinski","year":"2016","journal-title":"Br J Cancer"},{"key":"2025120102403359000_18.11.e266596.12","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.35.717"},{"key":"2025120102403359000_18.11.e266596.13","doi-asserted-by":"crossref","first-page":"5424","DOI":"10.3748\/wjg.v27.i32.5424","article-title":"Prolonged survival in patients with hand-foot skin reaction secondary to cooperative sorafenib treatment","volume":"27","author":"Ochi","year":"2021","journal-title":"World J Gastroenterol"},{"key":"2025120102403359000_18.11.e266596.14","first-page":"200","article-title":"Association of Hand-Foot Skin Reaction with Regorafenib Efficacy in the Treatment of Metastatic Colorectal Cancer","volume":"96","author":"Kobayashi","year":"2019","journal-title":"Oncology (Williston Park, NY)"},{"key":"2025120102403359000_18.11.e266596.15","doi-asserted-by":"crossref","first-page":"140","DOI":"10.14341\/serg9704","article-title":"Clinical evaluation of the effectiveness of treatment of the hand-foot syndrome \u2013 skin toxicity of antitumor target therapy with multi-kinase inhibitors","volume":"12","author":"Shatokhina","year":"2018","journal-title":"Endo Serg"},{"key":"2025120102403359000_18.11.e266596.16","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1159\/000322660","article-title":"Efficacy of Vitamin E Treatment for Hand-Foot Syndrome in Patients Receiving Capecitabine","volume":"5","author":"Yamamoto","year":"2010","journal-title":"Breast Care (Basel)"},{"key":"2025120102403359000_18.11.e266596.17","doi-asserted-by":"crossref","unstructured":"Graham J , Basappa NS , Ghosh S , et al . Association of Cabozantinib Dose Reductions for Toxicity with Clinical Effectiveness in Metastatic Renal Cell Carcinoma (mRCC): Results from the Canadian Kidney Cancer Information System (CKCis). American Society of Clinical Oncology, 2022.","DOI":"10.1200\/JCO.2022.40.6_suppl.316"},{"key":"2025120102403359000_18.11.e266596.18","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s11523-020-00736-8","article-title":"Management of Adverse Events Associated with Cabozantinib Treatment in Patients with Advanced Hepatocellular Carcinoma","volume":"15","author":"Schwartz","year":"2020","journal-title":"Target Oncol"},{"key":"2025120102403359000_18.11.e266596.19","article-title":"Cabozantinib Cutaneous Toxicity-Comprehensive Review","volume":"15","author":"Tutunaru","year":"2025","journal-title":"Life (Basel)"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2025-266596","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T10:40:39Z","timestamp":1764585639000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2025-266596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":19,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11,5]]},"published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1136\/bcr-2025-266596"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2025-266596","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]}}}